Kelly Barghausen, Ph.D. is Director, Regulatory Affairs at Priovant Therapeutics. She joined Priovant from Urovant, where she was Associate Director of Regulatory Affairs, making significant contributions to the EMPOWUR study and the submission and FDA approval of the original NDA for GEMTESA® (vibegron). Kelly started her career in Regulatory Affairs at Duke University and has a background in molecular genetics, oncology, and pre-clinical disease modeling. She holds a Ph.D. in Biomedical Sciences from Florida State University College of Medicine as well as a Regulatory Affairs Certification (RAC US).
This person is not in any offices
Priovant
2 followers
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens.